Globally, gastroesophageal adenocarcinomas (GEAs) impose an enormous health burden. In most of the world, diagnosis is made based on symptoms and not potential risk. This leads to high number of cases with advanced cancer at diagnosis. Advanced GEA patients face especial challenges such as nutritional deficiency, anemia, low-grade chronic bleeding, peritoneal carcinomatosis, and ovarian metastases (in females) in conjunction with lack of effective therapeutic options.